CX3CL1 at the crossroad of EGF signals relevance for the progression of ERBB2+ breast carcinoma

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Tardáguila, Manuel ^a   Mañes, Santos ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Chemokine; Cross activation; ERK; Fractalkine; Inflammation; MAPK; Tumor promotion

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRACTALKINE;

ARTICLE; BREAST CARCINOMA; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; METASTASIS POTENTIAL; NATURAL KILLER CELL; NONHUMAN; ONCOGENE NEU; TRANSACTIVATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84890278582     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25669     Document Type: Article

References (10)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j. cell.2011.02.013
2. González-Martin A, Mira E, Mañes S. CCR5 as a potential target in cancer therapy: inhibition or stimulation? Anticancer Agents Med Chem 2012; 12:1045-57; PMID:22583417; http://dx.doi. org/10.2174/187152012803529637
3. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91:521-30; PMID:9390561; http://dx.doi. org/10.1016/S0092-8674(00)80438-9
4. Kim KW, Vallon-Eberhard A, Zigmond E, Farache J, Shezen E, Shakhar G, et al. In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood 2011; 118:e156-67; PMID:21951685; http://dx.doi.org/10.1182/blood-2011-04-348946
5. Gaudin F, Nasreddine S, Donnadieu AC, Emilie D, Combadière C, Prévot S, et al. Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS One 2011; 6:e21546; PMID:21750716; http://dx.doi. org/10.1371/journal.pone.0021546
6. Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M, et al. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther 2007; 14:1226- 34; PMID:17597794; http://dx.doi.org/10.1038/ sj.gt.3302959
7. Tardáguila M, Mira E, García-Cabezas MA, Feijoo AM, Quintela-Fandino M, Azcoitia I, et al. CX3CL1 promotes breast cancer via transactivation of the EGF pathway. Cancer Res 2013; 73:4461-73; PMID:23720051; http://dx.doi.org/10.1158/0008- 5472.CAN-12-3828
8. Shiraishi K, Fukuda S, Mori T, Matsuda K, Yamaguchi T, Tanikawa C, et al. Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. Cancer Res 2000; 60:3722-6; PMID:10919640
9. Mira E, Lacalle RA, González MA, Gómez-Moutón C, Abad JL, Bernad A, et al. A role for chemokine receptor transactivation in growth factor signaling. EMBO Rep 2001; 2:151-6; PMID:11258708; http://dx.doi. org/10.1093/embo-reports/kve027
10. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402:884-8; PMID:10622253